Patents by Inventor Kailin YU
Kailin YU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11602534Abstract: The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFR? and/or PDGFR? kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.Type: GrantFiled: December 26, 2017Date of Patent: March 14, 2023Assignee: Hefei Institutes of Physical Science, Chinese Academy of SciencesInventors: Qingsong Liu, Jing Liu, Xiaofei Liang, Beilei Wang, Kailin Yu, Zongru Jiang, Cheng Chen, Chen Hu, Wenchao Wang, Fengming Zou, Qingwang Liu, Feng Li, Wenliang Wang, Li Wang
-
Publication number: 20220024931Abstract: The present application relates to a compound serving as a selective PI3K? kinase inhibitor, comprising the compound shown in formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined in the description. The present application also relates to a method for using the kinase inhibitor to inhibit PI3K? kinase activity or to treat or prevent diseases or conditions associated with tyrosine kinase activity of PI3K?, as well as a use thereof.Type: ApplicationFiled: December 12, 2018Publication date: January 27, 2022Applicant: TARAPEUTICS SCIENCE INC.Inventors: Qingsong LIU, Jing LIU, Xiaofei LIANG, Feng LI, Ziping QI, Zongru JIANG, Qingwang LIU, Kailin YU, Zhenquan HU, Beilei WANG, Li WANG
-
Publication number: 20200323850Abstract: The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFR? and/or PDGFR? kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.Type: ApplicationFiled: December 26, 2017Publication date: October 15, 2020Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCESInventors: Qingsong LIU, Jing LIU, Xiaofei LIANG, Beilei WANG, Kailin YU, Zongru JIANG, Cheng CHEN, Chen HU, Wenchao WANG, Fengming ZOU, Qingwang LIU, Feng LI, Wenliang WANG, Li WANG
-
Patent number: 10781214Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.Type: GrantFiled: December 27, 2016Date of Patent: September 22, 2020Assignee: PRECEDO PHARMACEUTICALS CO., LTD.Inventors: Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Hong Wu, Kailin Yu, Chen Hu, Wenchao Wang, Cheng Chen, Fengming Zou, Ziping Qi, Li Wang, Beilei Wang
-
Patent number: 10669238Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.Type: GrantFiled: December 22, 2016Date of Patent: June 2, 2020Assignee: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCESInventors: Jing Liu, Qingsong Liu, Qianmao Liang, Yongfei Chen, Cheng Chen, Aoli Wang, Hong Wu, Kailin Yu, Wei Wang, Chen Hu, Wenchao Wang, Shuang Qi, Beilei Wang, Li Wang
-
Patent number: 10266535Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).Type: GrantFiled: August 7, 2015Date of Patent: April 23, 2019Assignees: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, HEFEI COSOURCE PHARMACEUTICAL CO., LTD.Inventors: Jing Liu, Qingsong Liu, Xixiang Li, Aoli Wang, Hong Wu, Cheng Chen, Wenchao Wang, Chen Hu, Zheng Zhao, Jiaxin Wu, Juan Liu, Kailin Yu, Wei Wang, Li Wang, Beilei Wang
-
Publication number: 20190040013Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.Type: ApplicationFiled: December 22, 2016Publication date: February 7, 2019Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCESInventors: Jing LIU, Qingsong LIU, Qianmao LIANG, Yongfei CHEN, Cheng CHEN, Aoli WANG, Hong WU, Kailin YU, Wei WANG, Chen HU, Wenchao WANG, Shuang QI, Beilei WANG, Li WANG
-
Publication number: 20190010159Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.Type: ApplicationFiled: December 27, 2016Publication date: January 10, 2019Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong LIU, Jing LIU, Xixiang LI, Aoli WANG, Hong WU, Kailin YU, Chen HU, Wenchao WANG, Cheng CHEN, Fengming ZOU, Ziping QI, Li WANG, Beilei WANG
-
Publication number: 20180030054Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).Type: ApplicationFiled: August 7, 2015Publication date: February 1, 2018Applicants: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, HEFEI COSOURCE PHARMACEUTICAL CO., LTD.Inventors: Jing LIU, Qingsong LIU, Xixiang LI, Aoli WANG, Hong WU, Cheng CHEN, Wenchao WANG, Chen HU, Zheng ZHAO, Jiaxin WU, Juan LIU, Kailin YU, Wei WANG, Li WANG, Beilei WANG